Medicus Pharma: A New Era in Cardio-Sparing Prostate Cancer Treatment

Reimagining hormone therapy for men with advanced prostate cancer and heart risk

Advanced-stage prostate cancer affects up to 500,000 men in the U.S., many of whom also face a significant secondary risk: heart disease. Most current hormone therapies carry cardiovascular concerns—but Medicus Pharma is aiming to change that.

With a focus on cardio-oncology, Medicus is working on a new hormone therapy intended to reduce heart strain while maintaining efficacy in cancer treatment. Backed by a team that previously brought a breakthrough skin cancer patch to market, the company is now addressing a $4 billion opportunity in prostate cancer care. Their goal: safer outcomes for patients managing two life-threatening conditions.

‍

For more information on Medicus Pharma (NASDAQ: MDCX) please click on the request investor info button.

‍